Results 91 to 100 of about 70,621 (279)

Image Analysis Platform for Comprehensive Quantification of Extracellular Vesicle Morphology

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐encapsulated nanoparticles with key roles in cell biology and growing importance in biomedicine. However, EVs are challenging to characterize because they are highly heterogeneous. Single EV analysis methods are valuable tools for addressing this challenge.
Alexander Spark, Nan Jiang, Benjamin Purnell, Mihajlo Radmilovic, Andras Saftics, Eugenia Romano, Tijana Jovanovic‐Talisman, Alexandre Kitching   +7 more
wiley   +1 more source

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Breast Cancer Research, 2019
Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology.
Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig   +11 more
doaj   +1 more source

Acute Effect on QT Dispersion and Cardiac Function of Trastuzumab [PDF]

, 2014
Özgür Tanrıverdi
openalex   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery

VIEW, EarlyView.
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao, ZiKun Song, Weijie Zhou, Xiaohui Liu, Yanling Liu, Peng R. Chen, Kun Qian   +6 more
wiley   +1 more source

Endoscope‐Assisted Nipple‐Sparing Mastectomy With Immediate Implant Reconstruction: A Retrospective Study

World Journal of Surgery, EarlyView.
Breast cancer surgery increasingly favors nipple‐sparing and endoscopic techniques to optimize oncological safety, cosmetic outcomes, and patient satisfaction. We aimed to evaluate and compare the clinical efficacy and postoperative safety profiles of endoscope‐assisted and conventional open approaches for nipple‐sparing mastectomy with immediate ...
Yuan Shao, Youcheng Zhang, Huafeng Kang, Qing Zhou, Ziliang Zhang, Guiru Yan, Binghua Kan   +6 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer

eLife
Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies.
Yijia Hua, Ningjun Duan, Chunxiao Sun, Fan Yang, Min Tian, Yanting Sun, Shuhan Zhao, Jue Gong, Qian Liu, Xiang Huang, Yan Liang, Ziyi Fu, Wei Li, Yongmei Yin   +13 more
doaj   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

4CPS-071 Analysis of effectiveness: use of pertuzumab and trastuzumab in neoadjuvant treatment in patients with HER2 positive breast cancer and its correlation with plasma levels of trastuzumab [PDF]

, 2020
Rocío Álvarez Ambite, Fernando Gutiérrez Nicolás, I Ceballos Lezna, IJ Expósito Afonso, J González García, Ruth Tramontani Ramos, Josefina Cruz Jurado, GJ Nazco Casariego   +7 more
openalex   +1 more source